Fosun Pharmaceutical to Set Up Parallel Fund Structure

MT Newswires Live
04/01

Shanghai Fosun Pharmaceutical (Group) (SHA:600196, HKG:2196) plans to establish a parallel fund structure, which will consist of two funds that will invest in early-stage healthcare innovation projects, according to a Shanghai bourse filing on Wednesday.

The Tianjin Phase II Fund and the Hangzhou Fund will each have a target size of 1 billion yuan.

The pharmaceutical company will be a limited partner, investing 288 million yuan and 10 million yuan in Tianjin Phase II through two subsidiaries, and 348 million yuan in Hangzhou Fund through another designated subsidiary.

Fosun's Hong Kong shares rose 3% and Shanghai shares gained 2% during the morning trade.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10